Shattuck Labs, Inc. Investment Income, Interest
Shattuck Labs, Inc. (STTK) reported Investment Income, Interest of $1.03 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-11
- Shattuck Labs, Inc. investment income, interest for the quarter ending 2026-06-30 was $1.03M, a 27.99% increase year-over-year.
- Shattuck Labs, Inc. investment income, interest for the quarter ending 2026-03-31 was $779.00K, a 13.06% increase year-over-year.
- Shattuck Labs, Inc. investment income, interest for the quarter ending 2025-06-30 was $804.00K.
- Shattuck Labs, Inc. investment income, interest for the quarter ending 2025-03-31 was $689.00K.
- Shattuck Labs, Inc. investment income, interest for fiscal 2025 was $2.70M, a 47.76% decline from fiscal 2024.
- Shattuck Labs, Inc. investment income, interest for fiscal 2024 was $5.17M, a 10.82% increase from fiscal 2023.
- Shattuck Labs, Inc. investment income, interest for fiscal 2023 was $4.67M, a 193.28% increase from fiscal 2022.
- Shattuck Labs, Inc. investment income, interest for fiscal 2022 was $1.59M, a 154.72% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.03M 10-Q · filed 2026-08-11 | $1.83M 10-Q · filed 2026-08-11 | ||
| 2026-03-31 | $779.00K 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $2.70M 10-K · filed 2026-03-05 | |||
| 2025-06-30 | $804.00K 10-Q · filed 2026-08-11 | $1.42M 10-Q · filed 2026-08-11 | ||
| 2025-03-31 | $689.00K 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $5.17M 10-K · filed 2026-03-05 | |||
| 2023-12-31 | $4.67M 10-K · filed 2025-03-27 | |||
| 2022-12-31 | $1.59M 10-K · filed 2024-02-29 | |||
| 2021-12-31 | -$1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$1.07M derived: sum of 2 quarters · filed 2023-02-23 | -$71.00K derived: sum of 3 quarters · filed 2023-02-23 | $625.00K 10-K · filed 2023-02-23 |
| 2021-09-30 | $251.00K 10-Q · filed 2021-11-09 | $1.25M derived: sum of 2 quarters · filed 2021-11-09 | $1.95M 10-Q · filed 2021-11-09 | $2.02M derived: sum of 4 quarters · filed 2022-03-15 |
| 2021-06-30 | $1.00M 10-Q · filed 2021-08-12 | $1.70M 10-Q · filed 2021-08-12 | $1.77M derived: sum of 3 quarters · filed 2022-03-15 | $1.86M derived: sum of 4 quarters · filed 2022-03-15 |
| 2021-03-31 | $696.00K 10-Q · filed 2021-05-10 | $771.00K derived: sum of 2 quarters · filed 2022-03-15 | $857.00K derived: sum of 3 quarters · filed 2022-03-15 | $995.00K derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-12-31 | $75.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $161.00K derived: sum of 2 quarters · filed 2022-03-15 | $299.00K derived: sum of 3 quarters · filed 2022-03-15 | $549.00K 10-K · filed 2022-03-15 |
| 2020-09-30 | $86.00K 10-Q · filed 2021-11-09 | $224.00K derived: sum of 2 quarters · filed 2021-11-09 | $474.00K 10-Q · filed 2021-11-09 | $756.00K derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $138.00K 10-Q · filed 2021-08-12 | $387.00K 10-Q · filed 2021-08-12 | $670.00K derived: sum of 3 quarters · filed 2021-08-12 | $949.00K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $250.00K 10-Q · filed 2021-05-10 | $532.00K derived: sum of 2 quarters · filed 2021-05-10 | $811.00K derived: sum of 3 quarters · filed 2021-05-10 | |
| 2019-12-31 | $282.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $561.00K derived: sum of 2 quarters · filed 2021-03-16 | $1.18M 10-K · filed 2021-03-16 | |
| 2019-09-30 | $279.00K 10-Q · filed 2020-11-13 | $902.00K 10-Q · filed 2020-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |